Intercept Pharmaceuticals Stock Net Asset
ICPTDelisted Stock | USD 10.31 0.16 1.53% |
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Net Asset Analysis
Intercept Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Intercept Pharmaceuticals Net Asset | 553.71 M |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Intercept Pharmaceuticals has a Net Asset of 553.71 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Intercept Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in net asset category among its peers.
Intercept Fundamentals
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 695.84 M | |||
Shares Outstanding | 41.81 M | |||
Shares Owned By Insiders | 3.12 % | |||
Shares Owned By Institutions | 81.30 % | |||
Number Of Shares Shorted | 10.19 M | |||
Price To Earning | (3.88) X | |||
Price To Book | 44.19 X | |||
Price To Sales | 1.60 X | |||
Revenue | 285.71 M | |||
Gross Profit | 284.73 M | |||
EBITDA | (61.7 M) | |||
Net Income | (174.86 M) | |||
Cash And Equivalents | 404.78 M | |||
Cash Per Share | 13.58 X | |||
Total Debt | 332.67 M | |||
Debt To Equity | 411.20 % | |||
Current Ratio | 3.22 X | |||
Book Value Per Share | 1.72 X | |||
Cash Flow From Operations | (26.78 M) | |||
Short Ratio | 2.64 X | |||
Earnings Per Share | (4.26) X | |||
Price To Earnings To Growth | (0.69) X | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 | |||
Market Capitalization | 794.36 M | |||
Total Asset | 553.71 M | |||
Retained Earnings | (2.14 B) | |||
Working Capital | 310.05 M | |||
Current Asset | 641.69 M | |||
Current Liabilities | 47.37 M | |||
Z Score | -3.15 | |||
Net Asset | 553.71 M |
About Intercept Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intercept Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercept Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercept Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |